These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 7710436)

  • 21. Effect of naringin pretreatment on bioavailability of verapamil in rabbits.
    Yeum CH; Choi JS
    Arch Pharm Res; 2006 Jan; 29(1):102-7. PubMed ID: 16491851
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Unexpected effect of verapamil on oral bioavailability of the beta-blocker talinolol in humans.
    Schwarz UI; Gramatté T; Krappweis J; Berndt A; Oertel R; von Richter O; Kirch W
    Clin Pharmacol Ther; 1999 Mar; 65(3):283-90. PubMed ID: 10096260
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of simvastatin on the pharmacokinetics of verapamil and its main metabolite, norverapamil, in rats.
    Choi DH; Li C; Choi JS
    Eur J Drug Metab Pharmacokinet; 2009; 34(3-4):163-8. PubMed ID: 20166433
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Age and gender related changes in stereoselective pharmacokinetics and pharmacodynamics of verapamil and norverapamil.
    Gupta SK; Atkinson L; Tu T; Longstreth JA
    Br J Clin Pharmacol; 1995 Oct; 40(4):325-31. PubMed ID: 8554934
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Simultaneous analysis of the enantiomers of verapamil and norverapamil in rat plasma by liquid chromatography-tandem mass spectrometry.
    Mateus FH; Lepera JS; Marques MP; Boralli VB; Lanchote VL
    J Pharm Biomed Anal; 2007 Dec; 45(5):762-8. PubMed ID: 17981422
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Pharmacokinetics of verapamil and its N-dealkylated metabolites in patients with chronic ischemic heart disease undergoing long-term monotherapy].
    Rumiantsev DO; Piotrovskiĭ VK; Metelitsa VI; Riabokon' OS; Kokurina EV
    Farmakol Toksikol; 1988; 51(1):66-70. PubMed ID: 3360112
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Verapamil metabolite exposure in older and younger men during steady-state oral verapamil administration.
    Abernethy DR; Wainer IW; Anacleto AI
    Drug Metab Dispos; 2000 Jul; 28(7):760-5. PubMed ID: 10859149
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of verapamil and its metabolite norverapamil from a buccal drug formulation.
    Sawicki W; Janicki S
    Int J Pharm; 2002 May; 238(1-2):181-9. PubMed ID: 11996822
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors.
    Jacobson TA
    Am J Cardiol; 2004 Nov; 94(9):1140-6. PubMed ID: 15518608
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of oral epigallocatechin gallate on the oral pharmacokinetics of verapamil in rats.
    Chung JH; Choi DH; Choi JS
    Biopharm Drug Dispos; 2009 Mar; 30(2):90-3. PubMed ID: 19226653
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative pharmacokinetics of verapamil and norverapamil in normal and ulcerative colitis rats after oral administration of low and high dose verapamil by UPLC-MS/MS.
    Yao H; Wang C; Lu W; Li W; Jing W; Zhang J; Yang G; Zeng A
    Xenobiotica; 2020 Jun; 50(6):713-721. PubMed ID: 31633443
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Skin penetration of sulfamethoxazole and trimethoprim after oral administration].
    Królicki A
    Ann Acad Med Stetin; 2002; 48():59-73. PubMed ID: 14601469
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The absolute bioavailability and pharmacokinetics of butorphanol nasal spray in patients with hepatic impairment.
    Vachharajani NN; Shyu WC; Garnett WR; Morgenthien EA; Barbhaiya RH
    Clin Pharmacol Ther; 1996 Sep; 60(3):283-94. PubMed ID: 8841151
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetic study of intralesional cisplatin for the treatment of hepatocellular carcinoma.
    Mok TS; Kanekal S; Lin XR; Leung TW; Chan AT; Yeo W; Yu S; Chak K; Leavitt R; Johnson P
    Cancer; 2001 Jun; 91(12):2369-77. PubMed ID: 11413527
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Factors affecting the plasma protein binding of verapamil and norverapamil in man.
    Yong CL; Kunka RL; Bates TR
    Res Commun Chem Pathol Pharmacol; 1980 Nov; 30(2):329-39. PubMed ID: 7444161
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reduction of enantioselectivity in the kinetic disposition and metabolism of verapamil in rats exposed to toluene.
    Mateus FH; Lepera JS; Marques MP; Boralli VB; Lanchote VL
    Can J Physiol Pharmacol; 2008 May; 86(5):232-9. PubMed ID: 18432283
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stereoselective first-pass metabolism of verapamil in the small intestine and liver in rats.
    Hanada K; Ikemi Y; Kukita K; Mihara K; Ogata H
    Drug Metab Dispos; 2008 Oct; 36(10):2037-42. PubMed ID: 18617604
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
    Joerger M; Huitema AD; Meenhorst PL; Schellens JH; Beijnen JH
    Cancer Chemother Pharmacol; 2005 May; 55(5):488-96. PubMed ID: 15726371
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of atorvastatin on the intravenous and oral pharmacokinetics of verapamil in rats.
    Choi DH; Chang KS; Hong SP; Choi JS; Han HK
    Biopharm Drug Dispos; 2008 Jan; 29(1):45-50. PubMed ID: 17941000
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma levels and urinary excretion of verapamil, norverapamil, N-dealkylverapamil (D617), N-dealkylnorverapamil (D620) following oral administration of a slow-release preparation.
    Barbieri E; Padrini R; Piovan D; Toffoli M; Cargnelli G; Trevi G; Ferrari M
    Int J Clin Pharmacol Res; 1985; 5(2):99-107. PubMed ID: 4018947
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.